OAM
CSTL icon

Oberweis Asset Management’s Castle Biosciences CSTL Stock Holding History

Oberweis Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-26,260
Closed -$1.13M – 162
2021
Q4 		$1.13M Hold
26,260
– – 0.21% 85
2021
Q3 		$1.75M Sell
26,260
-47,800
-65% -$3.36M 0.36% 40
2021
Q2 		$5.43M Sell
74,060
-23,010
-24% -$1.52M 1.19% 13
2021
Q1 		$6.64M Sell
97,070
-66,040
-40% -$4.96M 1.36% 11
2020
Q4 		$11M Buy
163,110
+2,390
+1% +$130K 2.88% 5
2020
Q3 		$8.27M Buy
160,720
+1,730
+1% +$77K 2.78% 5
2020
Q2 		$5.99M Buy
158,990
+71,180
+81% +$2.43M 2.35% 8
2020
Q1 		$2.62M Buy
87,810
+36,610
+72% +$1.1M 1.44% 11
2019
Q4 		$1.76M Buy
+51,200
New +$1.25M 0.59% 28

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Oberweis Asset Management's CSTL Position: Q1 2022 in Review

Oberweis Asset Management sold out of Castle Biosciences (CSTL) in Q1 2022, closing a stake of 26,260 shares — an estimated $1.13M sold.

Oberweis Asset Management first reported a position in CSTL in Q4 2019 and held it in 9 quarters. The position peaked at $11M in Q4 2020. 160 funds tracked by Wall St. Rank hold CSTL as of Q1 2022.

  • Oberweis Asset Management reported no remaining Castle Biosciences position as of Q1 2022 after selling out during the quarter.
  • Oberweis Asset Management sold 26,260 Castle Biosciences shares in Q1 2022, an estimated $1.13M.
  • Oberweis Asset Management first reported a position in Castle Biosciences in Q4 2019 and held it in 9 quarters.
  • Oberweis Asset Management's Castle Biosciences position peaked at $11M in Q4 2020.
  • 160 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2022.

Based on Oberweis Asset Management's 13F filing for Q1 2022, filed 16 May 2022.